Possibility of using mathematical analysis methods to evaluate the potency of antibodies to hepatitis B virus surface antigen in human immunoglobulin preparations

Scientific relevance. Anti-hepatitis B virus surface-antigen (HBsAg) immunoglobulins are used to prevent hepatitis B in adults and children after exposure and to treat mild to moderate acute viral hepatitis B. The clinical effectiveness of human immunoglobulin preparations is determined by their potency, which is assessed by the content of antibodies to hepatitis B virus surface antigen (anti-HBs antibodies). Currently, this assessment involves using immunoassay techniques, such as enzyme-linked immunosorbent assay (ELISA).

Aim. This study examined several mathematical methods for analysing the experimental data obtained in ELISA-based anti-HBs antibody potency assays of human immunoglobulin preparations.

Materials and methods. This study used the international standard for human anti-HBs immunoglobulin, two immunoglobulin preparations, and an ELISA test kit for the detection and quantification of anti-HBs antibodies in serum or plasma samples.

Results. Using sandwich ELISA, the authors ascertained that the measured anti-HBs antibody concentration depended on the choice of calibration curve calculation method (i.e. manual analysis, parallel-line analysis using PARALINE software, linear regression, and 4-parameter logistic regression). The measured anti-HBs antibody concentrations varied by ± 19 IU/mL. According to the study results, an incorrectly selected method of data analysis can lead to an erroneous calculation of the analyte potency (concentration) in the test sample.

Conclusions. The study demonstrated the need for improved mathematical methods for the evaluation of experimental data used to determine the anti-HBs antibody concentration in human immunoglobulin preparations. It is essential to switch from manual to automated calculation (for example, using a 4-parameter logistic model), taking into account the requirements for bioanalytical methods and the capabilities of the available equipment.

1. Maddrey WC. Hepatitis B: an important public health issue. J Med Virol. 2000;61(3):362–6. https://doi.org/10.1002/1096-9071(200007)61:3%3C362::aid-jmv14%3E3.0.co;2-i

2. Tabatabaei MS, Ahmed М. Enzyme-Linked Immunosorbent Assay (ELISA). Methods Mol Biol. 2022;2508:115–34. https://doi.org/10.1007/978-1-0716-2376-3_10

3. Nechaev AV, Kudasheva EYu, Leshina SA, Kornilova OG, Konovalova ES, Struchkova IN, et al. Theoretical and experimental rationale of the selection of promising methods for quantitative determination of immunoglobulins G, A and M in human immunoglobulin products. Immunology. 2019;40(3):41–50 (In Russ.). https://doi.org/10.24411/0206-4952-2019-13005

4. Svezhova NV, Sharkova VE, Gromov DВ, Golovachenko VA, Polyntsev DG. Methods for mathematical data processing in enzyme immunoassay. I. Theoretical bases. Clinical Laboratory Diagnostics. 2008;(1):3–9 (In Russ.). EDN: IISVNB

5. Petukhov VG. Parallel-line method for quantitative assessment of the quality of standard samples and other MIBPs in enzyme immunoassay. BIOpreparations. Prevention, Diagnosis, Treatment. 2004;(1):19–23 (In Russ.).

6. Glantz SA. Primer of biostatistics. Moscow: Practice; 1998 (In Russ.).

7. Shanmugham R, Thirumeni N, Rao VS, Pitta V, Kasthuri S, Singanallur NB, et al. Immunocapture enzyme-linked immunosorbent assay for assessment of in vitro potency of recombinant hepatitis B vaccines. Clin Vaccine Immunol. 2010;17(8):1252–60. https://doi.org/10.1128/cvi.00192-10